Q-omics provides the consensus-scored NKX2-5 profile across patient tissues and cancer cell-line models. NKX2-5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NKX2-5 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, NKX2-5 RNA expression shows 11,387 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUSC, and TGCT as cancer lineages where NKX2-5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NKX2-5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NKX2-5 survival associations across molecular data types. NKX2-5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NKX2-5 RNA expression–survival associations across cancer types. High NKX2-5 expression shows unfavorable associations in KIRC, MESO, THCA, LGG, BLCA and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NKX2-5 RNA expression.
This table summarizes NKX2-5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NKX2-5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NKX2-5 shows lower tumor expression in THCA and higher tumor expression in LUSC, HNSC, UCEC, LUAD and KIRP. The LUSC box plot shows higher NKX2-5 RNA expression in tumor versus normal tissue (log2 FC = +1.876, t-test p < 0.001).
This table shows molecular features associated with NKX2-5 in patient tissues and cancer cell lines. In patient samples, NKX2-5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NKX2-5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
